A Randomised, Double-Blind, in Parallel Groups Placebo-Controlled, Mono-Centre, Phase I Study to Assess After Allergen Challenge in an Allergen Exposition Chamber the Effect and Its Time Course of Sublingual Immunotherapy (SLIT) Administered as 300IR Allergen-Based Tablets Once Daily to Adults Suffering From Grass Pollen Rhinoconjunctivitis.
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Stallergenes SA
- 14 Oct 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 01 Sep 2009 Results were published in the Journal of Allergy and Clinical Immunology.
- 17 Mar 2009 Results were reported at the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History